A new publication involving lanreotide was indexed on November 12, 2026. The article, titled "Recurrent Hypertensive Carcinoid Crisis Despite Somatostatin Analog Therapy," was published in the journal Cureus. Lanreotide is an approved somatostatin analog referenced in the publication's title. The publication is listed under PubMed ID 43022911. No findings, outcomes, or data from the publication have been provided beyond its title, journal, and publication date. This brief does not summarize or interpret the content of the case report. Readers interested in the full details of the case and its discussion should consult the original source listed below. For general background on lanreotide, including its approved regulatory status and mechanism, readers can refer to the compound overview for additional context.
Lanreotide Featured in New Cureus Case Report on Carcinoid Crisis
See the full lanreotide overview
Source: https://pubmed.ncbi.nlm.nih.gov/43022911/